Decreased IFT88 expression with primary cilia shortening causes mitochondrial dysfunction in cisplatin-induced

Rie Fujii1,2, Sho Hasegawa1,2, Hiroshi Maekawa1,2

  • 1Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Insights

Primary cilia shortening and decreased intraflagellar transport 88 (IFT88) expression impair kidney tubular function and mitochondrial health in acute kidney injury (AKI). This organelle cross-talk offers new therapeutic targets for AKI.

Area of Science:

  • Nephrology
  • Cell Biology
  • Mitochondrial Biology

Background:

  • Primary cilia play crucial roles in kidney function, but their involvement in acute kidney injury (AKI) and the underlying mechanisms remain unclear.
  • Mitochondrial dysfunction is a known contributor to tubular damage in AKI.

Purpose of the Study:

  • To investigate the interplay between primary cilia and mitochondria in cisplatin-induced AKI.
  • To elucidate the role of intraflagellar transport 88 (IFT88) in regulating primary cilia and mitochondrial function during AKI.

Main Methods:

  • Cisplatin-induced AKI mouse models and human proximal tubular cells (RPTEC/TERT1) were utilized.
  • IFT88 expression was modulated using siRNA knockdown (IFT88-KD) and overexpression.
  • Primary cilia length, mitochondrial oxidative phosphorylation, fatty acid oxidation, and ATP production were assessed.

Main Results:

  • Cisplatin treatment and IFT88 knockdown led to primary cilia shortening and decreased IFT88 expression in renal tubular cells.
  • Both conditions impaired mitochondrial oxidative phosphorylation, reduced fatty acid oxidation, and decreased ATP production.
  • IFT88 overexpression partially rescued mitochondrial function.

Conclusions:

  • A decrease in IFT88 expression and subsequent primary cilia shortening contribute to tubular mitochondrial dysfunction in cisplatin-induced AKI.
  • This study highlights a novel cross-talk between primary cilia and mitochondria in AKI pathogenesis.
  • Targeting the primary cilia-mitochondria interaction presents a potential therapeutic strategy for AKI.